// App-Quantinova.ai

2284 : Immune Cell Profiles in Patients Treated with Lenalidomide and Alternate Day Prednisolone Maintenance Post Upfront ASCT for Multiple Myeloma (LEOPARD Trial)

Researchers

Presenter

  • Anna Kalff

Principal Investigators

  • Sam Norton

  • Tiffany Khong

  • Malarmathy Ramachandran

  • Mary H. Young

  • William Pierceall

  • Anjan Thakurta

  • Udo Oppermann

  • Manman Guo

  • John Reynolds

  • Andrew Spencer

Medical Centers

  • Malignant Haematology & Stem Cell Transplantation Service, The Alfred, Prahran, Australia

  • Nanix Ltd, Dunedin, New Zealand

  • Myeloma Research Group, ACBD, Alfred Health-Monash University, Melbourne, Australia

  • Myeloma Research Group, Monash University, Melbourne, VIC, AUS

  • Celgene Corporation, Seattle, WA

  • Translational Medicine, Bristol-Myers Squibb, Summit, NJ

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

  • Oxford University, Oxford, United Kingdom

  • The Alfred and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia

  • Department of Clinical Haematology, Austin Hospital, Melbourne, Australia

Locations

  • Australia

  • New Zealand

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Natural Killer cells

  • C-C Motif Chemokine Receptor 7

  • Cluster of Differentiation 11c

  • Cluster of Differentiation 14

  • Cluster of Differentiation 19

  • Cluster of Differentiation 25

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 38

  • Cluster of Differentiation 4

  • Cluster of Differentiation 43

  • Cluster of differentiation 45

  • Cluster of Differentiation 5

  • Cluster of Differentiation 56

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Proliferation marker protein Ki-67

  • Cluster of differentiation 8A

  • Protein Tyrosine Phosphatase, Receptor Type C

  • C-X-C motif chemokine receptor 3

  • Fc gamma RIIIa

  • Human Leukocyte Antigen – DR isotype

  • Syndecan-1

  • Natural killer group 2D

Drug/Treatment

  • Lenalidomide

  • Prednisolone

  • Melphalan

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved